An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity.
Mechanism of action
Momelotinib competes with JAK1 and JAK2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells.
JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617.
The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.
Learn more about Momelotinib
- Dailymed label info on Momelotinib
- Scientific articles
- Drug portal Momelotinib
- toxicity info on Momelotinib
- FDA Momelotinib
Latest research - Momelotinib